ERBB2 and ovarian carcinoma: However, irrespective of the epitope recognised, our MD.45 effectors transduced to express this particular scFv (fused to the TCR ζ-chain) were capable of recognising and lysing HER-2/neu+ tumour cell lines from different types of cancer as well as primary HER-2/neu+ tumour cells from metastatic breast and ovarian cancers.